
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra Inc demonstrated significant growth in December, achieving its highest volume of VTE procedures ever and a remarkable 41% growth attributed to the Flash 2.0 product gaining market share. The company reported an increase in non-GAAP operating margin by 200 basis points year-over-year, driven by improvements in gross margin and reduced R&D expenses, culminating in an operating margin of 15.1%. Additionally, the overall Thrombectomy sales reached $222.7 million, reflecting a 16.9% increase, while gross margins improved to 67.4%, further highlighting the company’s financial health and operational efficiency.
Bears say
The analysis of Penumbra Inc presents a negative outlook primarily due to anticipated revenue growth decreasing to below 12%, attributed to weaker-than-expected contributions from new products and slow improvements in profitability. Additionally, the revised revenue estimates for 2025 and 2026 reflect a decline, adjusting from $1.363 billion to $1.349 billion and from $1.545 billion to $1.531 billion, respectively. Several risks further exacerbate this situation, including competitive pressures, margin challenges, delayed product clearances, and potential disruptions in supply chain or manufacturing processes.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares